NEXT GENERATION TOPICAL MEDICATION TO TREAT IMMUNE RESPONSES IN ATOPIC DERMATITIS – THE MOST COMMON CAUSE OF ECZEMA

Project description

Next-generation topical medication for the treatment of eczema

Fields of science

• medical and health sciences › health sciences › public and environmental health › epidemics prevention › immunisation
• medical and health sciences › clinical medicine › dermatology

Programme(s)

• H2020-EU.3. - PRIORITY 'Societal challenges
• H2020-EU.2.3. - INDUSTRIAL LEADERSHIP - Innovation In SMEs
• H2020-EU.2.1. - INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies

Topic(s)

• EIC-SMEInst-2018-2020 - SME instrument

Call for proposal

H2020-SMEInst-2018-2020-1
See other projects for this call

Funding Scheme

SME-1 - SME instrument phase 1

Coordinator

TIRMED PHARMA AB

Address

Spets Alviksvagen 1
16753 Bromma
Sweden

Activity type

Private for-profit entities (excluding Higher or Secondary Education Establishments)

EU contribution

€ 50 000